Tango Therapeutics, Inc. TNGX
Set alert
21.76 USD -0.96 -4.23%
At close · Nov 2
21.76 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
21.72 Day range 23.31
7.37 52-week range 34.39
- YTD
- +145.60%
- 1 year
- +168.31%
- Open
- 22.65
- Prev close
- 22.72
- Mkt cap
- 3.67B
- Vol
- 3.68M
- Avg vol
- 3.27M
- EPS
- -0.85
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 21.72
- High
- 23.31
- Forward P/E
- -12.91
- Beta
- 1.22
- Short ratio
- 11.90
- Inst. own
- 128.81%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 23.60
- 200-d avg
- 22.33
- 1y target
- 47.09
2Y chart
Events in this range
- Aug 5, 2025Earnings: -0.35; estimate -0.35; surprise 0%
- Nov 4, 2025Earnings: 0.13; estimate 0.01; surprise 1200%
- Mar 5, 2026Earnings: -0.29; estimate -0.31; surprise 6.45%
- May 13, 2026Earnings: -0.32; estimate -0.3137; surprise -2.01%
- Jul 15, 2026Rating: JP Morgan · — → Overweight
- Jul 17, 2026Rating: Mizuho · Outperform → Outperform
- Aug 10, 2026Earnings: -0.37; estimate -0.31722; surprise -16.64%
- Aug 12, 2026Rating: Guggenheim · Buy → Buy
- Aug 18, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 16, 2026Rating: William Blair · — → Outperform
- Oct 29, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (89)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 18 hours ago |
| MACD: Sell Signal | Oct 28, 2026 | 5 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 19, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 12, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 6, 2026 | 3 weeks ago |
| MACD: Buy Signal | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 1, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 24, 2026 | 4 months ago |
| RSI: Overbought | Jun 9, 2026 | 4 months ago |
Newest 20 of 89.
Key statistics
- Market cap
- 3.67B
- Enterprise value
- 2.85B
- Trailing P/E
- 0.00
- Forward P/E
- -12.91
- PEG ratio
- 0.00
- Price / sales
- 68.18
- Price / book
- 3.58
- EPS (TTM)
- -0.85
- Beta
- 1.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -229.92%
- Revenue (TTM)
- 53.81M
- Revenue growth
- 0.00%
- Free cash flow
- -71.87M
- Total cash
- 1.01B
- Total debt
- 31.99M
- Return on equity
- -21.34%
- Shares outstanding
- 168.61M
- Short % of float
- 26.86%
- 50-day average
- 23.60
- 200-day average
- 22.33
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 47.09 +116.4% upside
Now 21.76
- Target (low)
- 24.00
- Target (mean)
- 47.09
- Target (high)
- 69.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy1
- Buy11
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -0.35083.
Financials — quick view
TNGX Revenue — quarterly 0
TNGX Net income — quarterly -55.34M
TNGX EPS — quarterly -0.37
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.35297 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.31722 | -0.37 | -0.05 | -16.64% |
| May 13, 2026 | Mar 31, 2026 | -0.3137 | -0.32 | -0.01 | -2.01% |
| Mar 5, 2026 | Dec 31, 2025 | -0.31 | -0.29 | +0.02 | +6.45% |
| Nov 4, 2025 | Sep 30, 2025 | 0.01 | 0.13 | +0.12 | +1,200.00% |
| Aug 5, 2025 | Jun 30, 2025 | -0.35 | -0.35 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Aug 18, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 12, 2026 | Guggenheim | main | Buy | Buy |
| Jul 17, 2026 | Mizuho | main | Outperform | Outperform |
| Jul 15, 2026 | JP Morgan | init | — | Overweight |
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tangotx.com
News
- Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity
- HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target
- Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying
- Crude Oil Surges 4%; SLB Shares Jump Following Upbeat Q3 Earnings
- 10 Health Care Stocks Whale Activity In Today’s Session
- Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Tango Therapeutics Announces Results From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib In Patients With Metastatic Pancreatic Ductal Adenocarcinoma And Non-Small Cell Lung Cancer; Study Demonstrated 82% Objective Response Rate, Median PFS Not Yet Reached, And 9M PFS Rate Of 88%, In 22 Patients
- Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Moving Higher On Wednesday
- William Blair Initiates Coverage On Tango Therapeutics with Outperform Rating
Your note
Sign in to keep a note on TNGX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRY DOUGLAS | General Counsel | Sale | Feb 4, 2025 | 66,014 |
| BECKMAN DANIELLA | Chief Financial Officer | Sale | Feb 2, 2026 | 184,297 |
| BOXER CAPITAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 5, 2024 | 0 |
| BOXER CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 5, 2024 | 0 |
| CRYSTAL ADAM S | Officer | Sale | Sep 30, 2026 | 115,743 |
| ECOR1 CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 6, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 8.24% | 13,900,620 | 302.48M | Jun 29, 2026 |
| Blackrock Inc. | 7.38% | 12,438,444 | 270.66M | Jun 29, 2026 |
| FMR, LLC | 7.31% | 12,333,339 | 268.37M | Jun 29, 2026 |
| Farallon Capital Management LLC | 7.28% | 12,277,000 | 267.15M | Jun 29, 2026 |
| Boxer Capital Management, LLC | 6.45% | 10,876,219 | 236.67M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 5.92% | 9,980,620 | 217.18M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.61% | 4,395,732 | 95.65M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.41% | 4,065,305 | 88.46M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.16% | 3,649,644 | 79.42M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.67% | 2,809,158 | 61.13M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.48% | 2,500,062 | 54.40M | Aug 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.92% | 1,546,027 | 33.64M | Jun 29, 2026 |